The anticoagulant industry will observe considerable inclination with the rising prevalence of blood-related ailments. There is increasing adoption of anticoagulant products in the treatment of atrial fibrillation/flutter as well as coronary artery diseases. The Center for Disease Control and Prevention (CDC) estimated that over 1 million individuals in the U.S. were affected by coronary events in 2019. Out of these, 0.7 million accounted for new and 0.3 million suffered from recurrent coronary events.

Besides, several organizations, including the CDC and National Institutes of Health (NIH) are regulating initiatives and programs to increase consumer awareness levels.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/4967  

A recent report compiled by Global Market Insights, Inc., stated that the global anticoagulants market size will register close to USD 51.9 billion in terms of revenue by 2027.

Industry share of the heparin drug class segment reached USD 3.8 billion in 2020 and will grow at an exponential rate through 2027. This can be attributed to the advantages like lowered incidence of heparin-induced thrombocytopenia as well as resistance against activated platelets offered by the low molecular weight components. This anticoagulant also provides an enhanced bioavailability, extended half-life, and a decreased risk of osteoporosis.

Injectable anticoagulants held more than 57.2% of the overall share in 2020. This is owing to the higher usage of low molecular weight heparin among various other injectable drugs in the prevention and treatment of clots. The injectable anticoagulants are found to last for a longer span. They can also be effectively absorbed from the subcutaneous injection.

To quote an instance, dalteparin is considered the only injectable anticoagulant which has received approval for the extended treatment of venous thromboembolism in patients diagnosed with cancer. Moreover, the ease of access to these anticoagulants to tend to various conditions will boost the prospects for the industry.

The anticoagulants industry size from venous thromboembolism applications was valued at USD 1.9 billion in 2020 and will rise at a commendable speed in the next few years. This can be owed to the increasing prevalence of the disease. As per a report by the International Society on Thrombosis and Haemostasis (ISTH), there are over 10 million cases of venous thromboembolism (VTE) registered annually worldwide and close to 544,000 VTE related deaths are witnessed per year in Europe.

Online pharmacies were responsible for over 13.5% of the anticoagulants market share in 2020. This can be attributed to their advantages, including an extensive product portfolio, doorstep delivery as well as substantial discounts. This has resulted in a surge in the number of retail consumers. Besides, there is a growing popularity among millennials and the elderly population regarding online shopping across emerging countries.

Request for customization @ https://www.decresearch.com/roc/4967

Asia Pacific anticoagulants industry will expand at a prominent rate of 7.9% through 2027 due to the strong availability of a large patient pool across highly populous regions like China and India. There has been a significant hike in the number of chronic disorders in the continent. 

As per a report by the Asia Pacific Thrombosis Advisory Board, cardiovascular disease emerged as the most common disorder affecting the Asian population in 2019. It also mentioned that the incidence rate of coronary heart diseases, as well as myocardial infarction, had annually reached 150 per 100,000 population. In addition, there is also a robust presence of some of the leading mass local manufacturers in Southeast Asia.

Partial Chapter of the Table of Content:

Chapter 2.  Executive Summary

2.1. Anticoagulants industry 360° synopsis, 2016-2027

2.1.1.  Business trends

2.1.2.  Drug class trends

2.1.3.  Route of administration trends

2.1.4.  Application trends

2.1.5.  Distribution channel trends

2.1.6.  Regional trends

Chapter 3.  Anticoagulants Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2016 - 2027

3.3. Industry impact forces

3.3.1.  Growth drivers

3.3.1.1. Growing prevalence of chronic disease

3.3.1.2.    Growing adoption of novel oral anticoagulants (NOACs)

3.3.1.3.    Rising geriatric population across the globe

3.3.2.  Industry pitfalls & challenges

3.3.2.1. High risk of side effects

3.3.2.2.    Stringent regulatory framework

3.4. Growth potential analysis

3.4.1.  By drug class

3.4.2.  By route of administration

3.4.3.  By application

3.4.4.  By distribution channel

3.5. COVID-19 impact analysis

3.6. Porter’s analysis

3.7. Competitive landscape

3.7.1.  Company matrix analysis, 2019

3.8. PESTEL analysis

Browse complete Table of Contents (ToC) of this research report @ https://www.decresearch.com/toc/detail/anticoagulants-market